BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results

[GlobeNewswire] – Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM(TM) Underway; Positive CHMP Opinion Received February 20 more

View todays social media effects on BMRN

View the latest stocks trending across Twitter. Click to view dashboard

See who BioMarin is hiring next, click here to view